UBS Group’s Basel Medical BMGL Stock Holding History

UBS Group’s Portfolio BMGL Stock Details BMGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.44K	Sell	495 -593	-55%	-$4.36K	﹤0.01%	9191
2026 Q1	$7.7K	Buy	1,088 +414	+61%	+$3.27K	﹤0.01%	8559
2025 Q4	$3.96K	Buy	674 +182	+37%	+$2.69K	﹤0.01%	8912
2025 Q3	$10.7K	Buy	492 +22	+5%	+$552	﹤0.01%	8520
2025 Q2	$10K	Buy	+470	New	+$20.7K	﹤0.01%	8863

UBS Group's BMGL Position: Q2 2026 in Review

UBS Group reduced its Basel Medical (BMGL) stake by 55% in Q2 2026, selling an estimated $4.36K and leaving 495 shares worth $3.44K. The position accounts for ﹤0.01% of the portfolio, ranked #9191.

UBS Group first reported a position in BMGL in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.7K in Q3 2025. 2 funds tracked by Wall St. Rank hold BMGL as of Q2 2026.

UBS Group held 495 shares of Basel Medical worth $3.44K as of Q2 2026.
UBS Group sold 593 Basel Medical shares in Q2 2026, an estimated $4.36K.
Basel Medical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9191 holding.
UBS Group first reported a position in Basel Medical in Q2 2025 and has held it in 5 quarters since.
UBS Group's Basel Medical position peaked at $10.7K in Q3 2025.
2 funds tracked by Wall St. Rank held Basel Medical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.